20 participants
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-06-17
- Start Date:
- 2018-06-05
- Completion:
- 2023-09-30
Conditions
- Advanced Malignant Solid Neoplasm
- Recurrent Childhood Ependymoma
- Recurrent Childhood Malignant Germ Cell Tumor
- Recurrent Childhood Medulloblastoma
- Recurrent Childhood Non-Hodgkin Lymphoma
- Recurrent Childhood Osteosarcoma
- Recurrent Childhood Rhabdomyosarcoma
- Recurrent Childhood Soft Tissue Sarcoma
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Hepatoblastoma
- Recurrent Langerhans Cell Histiocytosis
- Recurrent Malignant Glioma
- Recurrent Malignant Solid Neoplasm
- Recurrent Neuroblastoma
- Recurrent Primary Central Nervous System Neoplasm
- Recurrent Rhabdoid Tumor
- Refractory Childhood Malignant Germ Cell Tumor
- Refractory Childhood Osteosarcoma
- Refractory Childhood Rhabdomyosarcoma
- Refractory Childhood Soft Tissue Sarcoma
- Refractory Ependymoma
- Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Refractory Hepatoblastoma
- Refractory Langerhans Cell Histiocytosis
- Refractory Malignant Glioma
- Refractory Malignant Solid Neoplasm
- Refractory Medulloblastoma
- Refractory Neuroblastoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Primary Central Nervous System Neoplasm
- Refractory Rhabdoid Tumor
- Wilms Tumor
Interventions
- PROCEDURE
- DRUG
- OTHER